Drifting Away from Informed Consent in the Era of Personalized Medicine
By Erik Parens,
The Hastings Center Report
| 07. 07. 2015
The price of sequencing all the DNA in a person's genome is falling
so fast that, according to one biotech leader, soon it won't cost
much more than flushing a toilet.1
Getting all that genomic data at an ever-lower cost excites the
imaginations not only of biotech investors and researchers but also of
the President and many members of Congress.2 They envision the data ushering in an age of “personalized medicine,” where medical care is tailored to persons’ genomes.
Since the 1990 start of the project to map the human genome,
sequencing advocates have been predicting our imminent arrival in the
Promised Land of Health. In 2000, when Francis Collins shared in
announcing the completion of a first draft of a human genome sequence,
he said that we now possessed the “book of life.”3
Soon, he foresaw, we would find single misspelled words in that book
that would be the keys to diagnosing, treating, and preventing both
common and rare diseases.
Since 2000, researchers have actually achieved some stunning
successes in personalized medicine, including making some definitive...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...